SEC sues biotech over alleged fraud

Proventus works to make awareness of new and novel treatments and attempts to present the information in such a manner that sufferers are able to make their own decisions and not be swayed by third parties. Proventus warned people about stem cell therapy clinics several years ago and was ignored. We have been making awareness of SF1019 for some years despite several attempts to silence us.

The Securities and Exchange Commission sued Immunosyn Corp. , three shareholder companies and four senior executives for allegedly misleading investors about the regulatory status of the company's sole product. Three executives were charged with insider trading. The SEC alleges that Immunosyn misleadingly stated in various public filings from 2006 to 2010 that its controlling shareholder - Argyll Biotechnologies LLC - either planned to commence or had commenced the U.S. regulatory approval process for human clinical trials for SF-1019, a drug derived from goat blood that was intended to treat a variety of ailments. The public filings failed to disclose that the U.S. Food and Drug Administration had already twice issued clinical holds on drug applications for SF-1019, prohibiting clinical trials from occurring, the SEC charged. The agency also said the company said a regulatory approval process in Europe was underway or imminent when no application was submitted.

Source - Market Watch - http://www.marketwatch.com/story/sec-sues-biotech-over-alleged-fraud-2011-08-02?siteid=yhoof2

The MS Society (UK) had stated on their web site, that there is anecdotal evidence for this drug, however without explanation they deleted the pages. There did not appear to be any indication of where the MS Society obtained or researched their data. Source - Copy on file.


The wheels of authority work slowly while the sufferer suffers